Gujarat Kidney And Super Speciality Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Gujarat Kidney And Super Speciality Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 93% of Healthcare companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹70 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 90% of Healthcare companies in India.
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹32 of operating cash. Lower than 86% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹32Over the last 3 years, every ₹100 of reported profit came with ₹32 of operating cash.
Lower than 86% of Healthcare companies in India.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
₹47For every ₹100 of sales, ₹47 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹2 tied up three years earlier.
More money tied up than 86% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
—Sales fell 29%
Sales fell 29% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-29% / +366%In 3 years sales changed by -29% while total assets changed by +366%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-0.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 93% of Healthcare companies in India.
Cash Cushion Ratio
+2%Cash, after subtracting all debt, equals 2% of its market value (net cash).
Higher than 68% of Healthcare companies in India.
Tangible Assets Ratio
70%Of every ₹100 the company owns, ₹70 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 90% of Healthcare companies in India.
Tangible Net Worth Ratio
64%Of every ₹100 of net worth, ₹64 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 84% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Gujarat Kidney And Super Speciality Limited owes ₹0.14 for every ₹1 it owns. Net profit rose 65% in the year to Mar 2026, and grew 33% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
70.7Investors pay ₹70.7 for every ₹1 of Gujarat Kidney And Super Speciality Limited's yearly profit, higher than 81% of Healthcare companies in India.
P/B ratio
5.60The share price is 5.60 times Gujarat Kidney And Super Speciality Limited's book value per share, higher than 61% of Healthcare companies in India.
Market cap
₹1,415 CrThe total market value of all of Gujarat Kidney And Super Speciality Limited's shares at today's price (share price × number of shares), smaller than 74% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹253 CrWhat Gujarat Kidney And Super Speciality Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹32.03Net worth divided by the number of shares. The share price of ₹179.46 is 5.6 times this, which is the P/B above.
Return on equity (ROE)
6.3%Gujarat Kidney And Super Speciality Limited earned 6.3% on its shareholders' money over the last year, lower than 80% of Healthcare companies in India.
Owes vs Owns
0.14×Gujarat Kidney And Super Speciality Limited owes ₹0.14 for every ₹1 it owns (low), lower than 94% of Healthcare companies in India.
Dividend yield
NoneGujarat Kidney And Super Speciality Limited does not currently pay a dividend.
Revenue growth
+65%Revenue rose 65% in the year to Mar 2026, and shrank 11% a year on average over 3 years.
Profit growth
+65%Net profit rose 65% in the year to Mar 2026, and grew 33% a year on average over 3 years.
Profit margin
25.6%Gujarat Kidney And Super Speciality Limited keeps ₹26 of every ₹100 of revenue as net profit.
Cash quality
-0.2×Cash from Gujarat Kidney And Super Speciality Limited's business was -0.2× its reported profit in the year to Mar 2026 — the business used cash even though it reported a profit.
Interest cover
0.5×Gujarat Kidney And Super Speciality Limited's operating profit covered its interest costs 0.5 times in the year to Mar 2026.
Cash vs debt
Net cashGujarat Kidney And Super Speciality Limited held ₹27 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Gujarat Kidney And Super Speciality Limited's P/E ratio?
Investors pay ₹70.7 for every ₹1 of Gujarat Kidney And Super Speciality Limited's yearly profit, higher than 81% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Gujarat Kidney And Super Speciality Limited: ₹1,415 Cr ÷ ₹253 Cr (31 Mar 2026) = 5.6.
What is Gujarat Kidney And Super Speciality Limited's return on equity?
Gujarat Kidney And Super Speciality Limited earned 6.3% on its shareholders' money over the last year, lower than 80% of Healthcare companies in India.
How much does Gujarat Kidney And Super Speciality Limited owe compared with what it owns?
Gujarat Kidney And Super Speciality Limited owes ₹0.14 for every ₹1 it owns (low), lower than 94% of Healthcare companies in India.
Does Gujarat Kidney And Super Speciality Limited pay a dividend?
No. Gujarat Kidney And Super Speciality Limited does not currently pay a dividend.
Is Gujarat Kidney And Super Speciality Limited's revenue growing?
Revenue rose 65% in the year to Mar 2026, and shrank 11% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.